NeuraLight Overview
NeuraLight is building an AI-driven platform to accelerate and improve drug development, monitoring, and care for patients with neurological disorders by using information captured with a standard smartphone or webcam. The companys platform automatically extracts micro-oculometrics, providing objective and sensitive digital markers for neurological disorders. The solution is designed to serve as a robust proxy for currently used endpoints and to ultimately define a new measurement standard, paving the path for precision medicine in neurology. NeuraLight is focused on transforming the lives of the billions of people impacted by neurological disorders by digitizing patient evaluation and care. Its vision is a world where neurological disorders can be prevented, diagnosed, and treated effectively so that people can live longer, healthier lives.
Cumulative Funding Raised Over Time ($)
$25.0MMay 2022
$30.5MOct 2021
Latest News
growth-positive
New assessment tool for ALS based on abnormal eye movements
NeuraLights software platform, which evaluates eye movement abnormalities, could be used as an assessment tool for patients with amyotrophic lateral sclerosis (ALS), according to research published in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal. The use of the platform correlated with current gold-standard clinical assessments, making it a viable adjunct assessment tool. The technology can be implemented in clinical trials and also as part of a routine assessment for ALS patients.
Customers
NeuraLight is making neurological diagnostics more precise
growth-positive
NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI CTech
NeuraLight, an Israeli company that develops biomarkers for neurological diseases, has announced a collaboration with NeuroSense Therapeutics to promote research on degenerative neurological diseases, including ALS. The collaboration involves monitoring patients and sharing data to improve diagnoses and the use of digital biomarkers. NeuraLight recently raised $25 million in funding and this collaboration marks their first clinical trial. ALS is an incurable neurodegenerative disease, and the collaboration aims to develop disease-modifying therapies. The collaboration is seen as a long-term partnership, with future studies planned for Alzheimers and Parkinsons diseases.
PartnersCustomers
growth-positive
NeuraLight secures $25 million in Series A
NeuraLight, an Israeli startup developing precision medicine for neurological diseases using computer vision and smartphones, has raised $25 million in a Series A funding round. The round was led by Koch Disruptive Technologies, with participation from Breyer Capital, Samsung NEXT, VSC Ventures, and Viz.ai co-founders Chris Mansi and David Golan. The company plans to use the new capital to improve the design of neurological clinical trials, increase the probability of success for novel neurological therapeutics, and usher in a new era of precision medicine for neurology.
Investment
growth-positive
NeuraLight appoints Dr. Gil Shklarski as Scientific Co-founder and Board Observer
NeuraLight, a company specializing in digitizing neurological insights using AI, has appointed Dr. Gil Shklarski as Scientific Co-founder and Board Observer. Dr. Shklarski, who previously served as CTO of Flatiron Health, will help NeuraLight in its growth phase from Seed to Series A. He believes in the potential of NeuraLights team and technology to transform the lives of people with neurological disorders. NeuraLight launched in October 2021 with a $5.5 million investment co-led by MSAD.vc, Kli Capital, and Tuesday Capital. Dr. Shklarski will work closely with management to define the strategic playbook and execute the commercial aspects as the company prepares for its first clinical trials.
Management ChangesInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $30.5M |
| Last funding | $25M |
| Stage | A |
| Rounds | 2 |
| Investors | 9 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | neuralight.ai |
| Careers | Careers page |
Locations
Tel Aviv, Israel
Photos & Videos
1 item(s)
NeuraLight Business
Business models
B2B
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesDigital HealthcareDigital Medical DiagnosticsTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcareProvidersCore Technology
Platforms & InterfacesSoftwareArtificial IntelligenceComputer VisionDeep LearningTags (20)
degenerative-diseasesalzheimers-diseasevideohealthcare-providersparkinsondeep-learningautomationpharma-companiesdrug-developmentcomputer-visiondiagnosticssignal-processingartificial-intelligencemultiple-sclerosisweb-platformdigital-healthcaredecision-supportmobile-applicationstelemedicineneurologyNeuraLight Financials
$30.5M
Total funding
Undisclosed
Capital raised
$25M
Last funding
A
Funding stage
2
Total rounds
9
Investors
Cumulative Funding Raised Over Time ($)
$25.0MMay 2022
$30.5MOct 2021
Private Equity Funding
A Round
May 2022
$25M
Koch Disruptive Technologies (Lead)
,
Samsung Next TLV, Chris Mansi, David Golan, Breyer Capital
Seed
Oct 2021
$5.5M
MS&AD Ventures (Lead)
,
VSC Ventures, Operator Partners, Kli Capital
NeuraLight Lifecycle
Cumulative Funding Raised Over Time
$25.0MMay 2022
$30.5MOct 2021
All Events
A Round
May 2022
$25M
Koch Disruptive Technologies (Lead)
,
Samsung Next TLV, Chris Mansi, David Golan, Breyer Capital
Seed
Oct 2021
$5.5M
MS&AD Ventures (Lead)
,
VSC Ventures, Operator Partners, Kli Capital
NeuraLight News
8 articles
growth-positive
New assessment tool for ALS based on abnormal eye movements
NeuraLights software platform, which evaluates eye movement abnormalities, could be used as an assessment tool for patients with amyotrophic lateral sclerosis (ALS), according to research published in the Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal. The use of the platform correlated with current gold-standard clinical assessments, making it a viable adjunct assessment tool. The technology can be implemented in clinical trials and also as part of a routine assessment for ALS patients.
Customers
NeuraLight is making neurological diagnostics more precise
growth-positive
NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI CTech
NeuraLight, an Israeli company that develops biomarkers for neurological diseases, has announced a collaboration with NeuroSense Therapeutics to promote research on degenerative neurological diseases, including ALS. The collaboration involves monitoring patients and sharing data to improve diagnoses and the use of digital biomarkers. NeuraLight recently raised $25 million in funding and this collaboration marks their first clinical trial. ALS is an incurable neurodegenerative disease, and the collaboration aims to develop disease-modifying therapies. The collaboration is seen as a long-term partnership, with future studies planned for Alzheimers and Parkinsons diseases.
PartnersCustomers
growth-positive
NeuraLight secures $25 million in Series A
NeuraLight, an Israeli startup developing precision medicine for neurological diseases using computer vision and smartphones, has raised $25 million in a Series A funding round. The round was led by Koch Disruptive Technologies, with participation from Breyer Capital, Samsung NEXT, VSC Ventures, and Viz.ai co-founders Chris Mansi and David Golan. The company plans to use the new capital to improve the design of neurological clinical trials, increase the probability of success for novel neurological therapeutics, and usher in a new era of precision medicine for neurology.
Investment
growth-positive
NeuraLight appoints Dr. Gil Shklarski as Scientific Co-founder and Board Observer
NeuraLight, a company specializing in digitizing neurological insights using AI, has appointed Dr. Gil Shklarski as Scientific Co-founder and Board Observer. Dr. Shklarski, who previously served as CTO of Flatiron Health, will help NeuraLight in its growth phase from Seed to Series A. He believes in the potential of NeuraLights team and technology to transform the lives of people with neurological disorders. NeuraLight launched in October 2021 with a $5.5 million investment co-led by MSAD.vc, Kli Capital, and Tuesday Capital. Dr. Shklarski will work closely with management to define the strategic playbook and execute the commercial aspects as the company prepares for its first clinical trials.
Management ChangesInvestment
growth-positive
The answer to Parkinson's and Alzheimer's is all in your eyes
Tel Aviv and Austin-based startup Neuralight has launched with a $5.5 million seed investment. The company aims to digitize and automate neurological evaluation and care by developing a technology that can decode data from the eyes. Neuralights platform extracts microscopic eye movement measurements that serve as digital endpoints for neurological disorders. The company plans to sell the data to pharmaceutical companies to accelerate drug development. Neuralights technology has the potential to make drug development for neurological diseases more effective. The company is in conversations with three large pharma companies and hopes to receive FDA clearance by the end of 2022.
InvestmentExpand
growth-positive
NeuraLight Raises $5.5M in Seed Funding - FinSMEs
NeuraLight, a company treating neurological disorders by digitizing neurology care, has raised $5.5 million in seed funding. The funding will be used to enhance the lives of people suffering from neurological disorders by digitizing neurological evaluation and care. NeuraLight uses proprietary Computer Vision and Deep Learning algorithms to capture objective and sensitive digital markers to help accelerate drug development and increase the success rates of new drugs. The platform can be integrated into clinical trials and remote settings, improving the patient experience. The companys team includes industry experts and advisors from the pharmaceutical and healthcare sectors.
Investment
growth-positive
How can startups leverage controversial FDA approval for Alzheimer's drug?
The FDAs approval of Biogens Alzheimers drug, Aducanumab, presents a significant opportunity for neurology-focused startups to address the challenges in the field. Neurological disorders affect over one billion people worldwide, and the lack of objective measurements has hindered progress in the field. Startups have successfully leveraged AI and machine learning in other medical disciplines, but neurology has lagged behind. The approval of Aducanumab highlights the need for objective and sensitive measurements in neurological drug development. Startups have the potential to introduce novel technologies and biomarkers that can revolutionize neurological treatment. By utilizing advanced computer vision, machine learning, and innovative approaches, startups can provide continuous monitoring and predictive models for neurological disorders. This presents a growth-positive opportunity for companies like NeuraLight, which aims to digitize neurology and transform the lives of people with neurological disorders.
InvestmentExpand
NeuraLight Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 39 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 13 classification IDs that could be used for matching.
NeuraLight Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 516350998 |
| Crunchbase | neuralight-3df0 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2023-07-31T00:00:00.000Z |
| Created | 2021-03-04T00:00:00.000Z |